Gregory E Simon1, Evette J Ludman. 1. Group Health Cooperative, Center for Health Studies, Seattle, WA 98101, USA. simon.g@ghc.org <simon.g@ghc.org>
Abstract
OBJECTIVE: The objective of this study was to examine the indications for benzodiazepine use, and the baseline characteristics, duration of use and clinical outcomes of older primary care patients prescribed benzodiazepines. METHODS: Computerized records were used to identify outpatients (n=129) aged >or=60 years who received new benzodiazepine prescriptions from primary care physicians of a group model managed care organization. A baseline telephone survey assessed indications for prescription, sleep quality (Pittsburgh Sleep Quality Index), depression (Symptom Checklist depression scale and Structured Clinical Interview for DSM-IV), alcohol use (CAGE) and functional status (SF-36). A 2-month follow-up survey assessed benzodiazepine use, sleep quality and depression. RESULTS: The most common indications for prescription were insomnia (42%) and anxiety (36%). At baseline, participants reported moderate sleep disturbance (mean Pittsburgh Sleep Quality Index=9.3, S.D.=4.0), only 15% met criteria for current depressive episode and only 3% reported at-risk alcohol use. After 2 months, 30% of participants used benzodiazepines at least daily. Both those continuing daily use and those not continuing daily use reported significant improvements in sleep quality and depression, with no difference between groups in rates of improvement. CONCLUSIONS: Initial benzodiazepine prescriptions to older adults are typically intended for the treatment of anxiety or insomnia, with little evidence for occult depression or alcohol abuse. A significant minority develops a pattern of long-term use, raising concerns about tolerance and dependence.
OBJECTIVE: The objective of this study was to examine the indications for benzodiazepine use, and the baseline characteristics, duration of use and clinical outcomes of older primary care patients prescribed benzodiazepines. METHODS: Computerized records were used to identify outpatients (n=129) aged >or=60 years who received new benzodiazepine prescriptions from primary care physicians of a group model managed care organization. A baseline telephone survey assessed indications for prescription, sleep quality (Pittsburgh Sleep Quality Index), depression (Symptom Checklist depression scale and Structured Clinical Interview for DSM-IV), alcohol use (CAGE) and functional status (SF-36). A 2-month follow-up survey assessed benzodiazepine use, sleep quality and depression. RESULTS: The most common indications for prescription were insomnia (42%) and anxiety (36%). At baseline, participants reported moderate sleep disturbance (mean Pittsburgh Sleep Quality Index=9.3, S.D.=4.0), only 15% met criteria for current depressive episode and only 3% reported at-risk alcohol use. After 2 months, 30% of participants used benzodiazepines at least daily. Both those continuing daily use and those not continuing daily use reported significant improvements in sleep quality and depression, with no difference between groups in rates of improvement. CONCLUSIONS: Initial benzodiazepine prescriptions to older adults are typically intended for the treatment of anxiety or insomnia, with little evidence for occult depression or alcohol abuse. A significant minority develops a pattern of long-term use, raising concerns about tolerance and dependence.
Authors: Joseph T Hanlon; Kenneth E Schmader; Chad Boult; Margaret B Artz; Cynthia R Gross; Gerda G Fillenbaum; Christine M Ruby; Judith Garrard Journal: J Am Geriatr Soc Date: 2002-01 Impact factor: 5.562
Authors: Shelly L Gray; Brenda W J H Penninx; David K Blough; Margaret B Artz; Jack M Guralnik; Robert B Wallace; Dave M Buchner; Andrea Z LaCroix Journal: J Am Geriatr Soc Date: 2003-11 Impact factor: 5.562
Authors: Christopher C Colenda; Deborah B Wagenaar; Maureen Mickus; Steven C Marcus; Terri Tanielian; Harold Alan Pincus Journal: Am J Geriatr Psychiatry Date: 2003 Jul-Aug Impact factor: 4.105
Authors: Shelly L Gray; Anne Elise Eggen; David Blough; Dave Buchner; Andrea Z LaCroix Journal: Am J Geriatr Psychiatry Date: 2003 Sep-Oct Impact factor: 4.105
Authors: Lauren B Gerlach; Donovan T Maust; Shirley H Leong; Shahrzad Mavandadi; David W Oslin Journal: JAMA Intern Med Date: 2018-11-01 Impact factor: 21.873
Authors: Shannon M L Furbish; Miranda E Kroehl; Danielle F Loeb; Huong Mindy Lam; Carmen L Lewis; Jennifer Nelson; Zeta Chow; Katy E Trinkley Journal: J Pharm Pract Date: 2016-08-01